The expression of COX-2 and VEGF was inactivated by tanshinone II-A, miR-101, and andrographolide in tumor cells, while the andrographolide impaired COX-2 promoter activity and restricted multiple trans-activators to bind the COX-2 promoter, such as CREB-2, c-Fos, and NF-κB (Zhou et al., 2012a; Liu et al., 2018a; Peng et al., 2018). The gene discussed is NFKB1; the disease is neoplasm.